Biogen Resets Aduhelm Expectations, Expects Longer, Slower Path To Significant Sales
Best Case Scenario: Meaningful Patient Access Over Time
The company reported $1m in Q4 sales of its Alzheimer’s drug. Biogen expects Aduhelm to make a minimal contribution to full-year 2022 revenues, which will total about $1bn less than in 2021.
You may also be interested in...
Biogen’s Aduhelm Competitors Boosted By Final CMS Coverage Decision
The Center for Medicare and Medicaid Services’ final decision on Medicare coverage favors anti-amyloid antibodies approved for Alzheimer’s disease based on efficacy rather than biomarker data.
Eisai Gives Full Aduhelm Responsibility To Biogen Under Amended Agreement
The companies amended the terms of their Alzheimer’s collaboration to give Biogen full decision-making control over Aduhelm immediately. Eisai’s 50% share of profits and losses from the drug switches to a 2% royalty in 2023. The partners’ agreement for Eisai-led lecanemab remains intact.
Lilly Waiting On Phase III Data For Donanemab
Lilly no longer plans to complete an accelerated approval submission for Alzheimer’s candidate donanemab during Q1 following the CMS draft coverage decision for amyloid-targeting therapies.